Last reviewed · How we verify

EMD Serono — Portfolio Competitive Intelligence Brief

EMD Serono pipeline: 6 marketed, 0 filed, 4 Phase 3, 8 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 4 Phase 3 8 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Luveris® 25 IU Luveris® 25 IU marketed
Rebif® Rebif® marketed
Saizen® Saizen® marketed
Luveris® 75 IU Luveris® 75 IU marketed
Serostim® Serostim® marketed Growth hormone (recombinant human somatropin) Growth hormone receptor (GHR) Infectious Disease / Endocrinology
Antagon ™ Antagon ™ marketed GnRH antagonist GnRH receptor Reproductive Medicine / Fertility
Rebif New Formulation Titrated Rebif New Formulation Titrated phase 3 Interferon IFNAR Immunology
Rebif New Formulation Non Titrated Rebif New Formulation Non Titrated phase 3 Interferon IFNAR Immunology
Ribavirin plus Interferon-beta-1a Ribavirin plus Interferon-beta-1a phase 3 Antiviral combination (nucleoside analog + cytokine) Viral RNA polymerase (ribavirin); Interferon-alpha/beta receptor (interferon-beta-1a) Virology/Infectious Disease
Interferon-beta-1a FBS-free/HSA-free Interferon-beta-1a FBS-free/HSA-free phase 3 Interferon Interferon-alpha/beta receptor (IFNAR) Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Merck Sharp & Dohme LLC · 2 shared drug classes
  2. Anhui Shi, MD · 1 shared drug class
  3. Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 shared drug class
  4. AstraZeneca · 1 shared drug class
  5. Bayer · 1 shared drug class
  6. Biogen · 1 shared drug class
  7. Assaf-Harofeh Medical Center · 1 shared drug class
  8. Active Biotech AB · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for EMD Serono:

Cite this brief

Drug Landscape (2026). EMD Serono — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/emd-serono. Accessed 2026-05-13.

Related